Kinfo
Orchestra BioMed Holdings, Inc. logo

Orchestra BioMed Holdings, Inc.

OBIONASDAQHealthcare·US · USD
$6.05
+0.10 (+1.68%)
Prices as of October 5, 2026 · live

Price

Key statistics

Valuation
Market cap357.63M USD
Enterprise value328.52M USD
Trailing P/E-5.46
Forward P/E-3.94
PEG ratio0.23
Price / sales11.18
Price / book18.54
Profitability
Gross margin71.59%
Operating margin-25404.55%
Profit margin-184.60%
Return on assets-45.73%
Return on equity-397.30%
Income (TTM)
Revenue31.98M USD
Gross profit31.82M USD
EBITDA-57.64M USD
Net income-59.57M USD
Diluted EPS-$0.84
Rev. growth (YoY)-89.50%
Balance sheet
Total cash109.96M USD
Total debt70.76M USD
Debt / equity240.52
Current ratio8.26
Book value / share$0.32
Cash flow (TTM)
Operating cash flow-58.32M USD
Levered free cash flow-31.81M USD
Shares & price
Shares outstanding60.11M
Float32.95M
Held by institutions47.80%
Beta0.53
50-day MA$5.15
200-day MA$4.40
52-week high$6.50
52-week low$2.66
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-10-0.37-0.37+0.00%2026-07-241.551.68+8.39%2026-06-18-0.20-0.08+60.00%2026-03-12-0.380.26+168.42%
About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing therapeutic technologies for cardiovascular disease and related medical conditions. Its current portfolio centers on AVIM Therapy, a bioelectronic treatment candidate designed to help lower blood pressure in patients with pacemakers, and Virtue Sirolimus AngioInfusion Balloon, a drug-device platform intended for treating atherosclerotic artery disease. The company also works on cardiac neuromodulation programs and minimally invasive device technologies that support interventional procedures. Orchestra BioMed’s business model relies on partnerships with established medical device companies to advance clinical development and commercialization. Headquartered in New Hope, Pennsylvania, Orchestra BioMed plays a niche role in the medical technology market by combining device innovation, bioelectronic therapy, and targeted drug delivery within cardiovascular care.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. David P. Hochman
Employees
86
Headquarters
New Hope, PA, United States

Frequently asked questions about Orchestra BioMed Holdings, Inc.